Table 4 Analysis of the relationship between HBV infection and thalassemia mutations in the retrospective cohort used in the validation phase.
Healthy controls (n = 129) | HBV infection (n = 86) | OR (95% CI) | P values | |
|---|---|---|---|---|
Non-thalassemia carrier | 87 (67.4%) | 58 (67.4%) | ||
Thalassemia carrier (total) | 42 (32.6%) | 28 (32.6%) | 1.00 (0.55–1.76) | n.s. |
α-thalassemia silent carrier | 24 (18.6%) | 20 (23.3%) | 1.25 (0.63–2.42) | n.s. |
α-thalassemia minor | 17 (13.1%) | 7 (8.1%) | 0.62 (0.24–1.67) | n.s. |
β-thalassemia minor | 1 (0.01%) | 0 (0%) | 0.00 (0.00-13.66) | n.s. |
α-thalassemia minor + β-thalassemia minor | 0 (0%) | 1 (0.01%) | ∞ (0.16-∞) | n.s. |
